SALT LAKE CITY — In this video, Jay Chhablani, MD, professor of ophthalmology at University of Pittsburgh School of Medicine, discusses 24-month findings from the SAGA trial evaluating oral gildeuretinol for geographic atrophy.
Daily 14 mg gildeuretinol (Alkeus Pharmaceuticals) was associated with a reduction in GA lesion growth, with greater reductions occurring between months 6 and 24, Chhablani said. Patients also had less visual acuity loss and improved quality of life scores, he said.
“Instead of injections, they are getting oral treatment, so the quality of life testing also